Increased lung expression of anti-angiogenic factors in Down syndrome: Potential role in abnormal lung vascular growth and the risk for pulmonary hypertension

PLoS ONE

Volumn 11, Issue 8, 2016, Pages

  Galambos, Csaba ^a   Minic, Angela D ^a   Bush, Douglas ^a   Nguyen, Dominique ^b   Dodson, Blair ^a   Seedorf, Gregory ^a   Abman, Steven H ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NOTRE DAME   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; ENDOSTATIN; MESSENGER RNA; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TUMSTATIN; AMYLOID PRECURSOR PROTEIN; APP PROTEIN, HUMAN; AUTOANTIGEN; COL18A1 PROTEIN, HUMAN; COLLAGEN TYPE 4; COLLAGEN TYPE 8; MUSCLE PROTEIN; RCAN1 PROTEIN, HUMAN; SIGNAL PEPTIDE; TIMP3 PROTEIN, HUMAN; TYPE IV COLLAGEN ALPHA3 CHAIN;

ANGIOGENESIS; APP GENE; ARTICLE; BLOOD VESSEL WALL; COL18A1 GENE; COL4A3 GENE; CONTROLLED STUDY; DOWN SYNDROME; FETUS LUNG; GENE EXPRESSION; HUMAN; HUMAN TISSUE; INFANT; LUNG BLOOD VESSEL; LUNG DEVELOPMENT; LUNG PARENCHYMA; NEWBORN; PATHOGENESIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TIMP3 GENE; UPREGULATION; ABNORMALITIES; COMPLICATION; DNA MICROARRAY; EMBRYOLOGY; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; LUNG; METABOLISM; PREGNANCY;

AMYLOID BETA-PROTEIN PRECURSOR; AUTOANTIGENS; COLLAGEN TYPE IV; COLLAGEN TYPE VIII; DOWN SYNDROME; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, DEVELOPMENTAL; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LUNG; MUSCLE PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PREGNANCY; TISSUE INHIBITOR OF METALLOPROTEINASE-3; UP-REGULATION;

EID: 84983656474     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0159005     Document Type: Article

References (37)

1. McDowell KM, Craven DI. Pulmonary complications of Down syndrome during childhood. The Journal of pediatrics. 2011; 158(2):319-25. doi: 10.1016/j.jpeds.2010.07.023 PMID: 20846671.
2. Salinas M, Elawabdeh N, Lin J, Naguib MM, Hodge MG, Shehata BM. The spectrum of pulmonary malformation in trisomy-21 patient. A review with emphasis on the molecular-genetic basis. Fetal and pediatric pathology. 2013; 31(1):38-42. doi: 10.3109/15513815.2012.659415 PMID: 22497682.
3. Watts R, Vyas H. An overview of respiratory problems in children with Down's syndrome. Archives of disease in childhood. 2013; 98(10):812-7. doi: 10.1136/archdischild-2013-304611 PMID: 23814080.
4. Yang Q, Rasmussen SA, Friedman JM. Mortality associated with Down's syndrome in the USA from 1983 to 1997: a population-based study. Lancet. 2002; 359(9311):1019-25. PMID: 11937181.
5. Cua CL, Blankenship A, North AL, Hayes J, Nelin LD. Increased incidence of idiopathic persistent pulmonary hypertension in Down syndrome neonates. Pediatric cardiology. 2007; 28(4):250-4. doi: 10.1007/s00246-006-0011-6 PMID: 17486396.
6. Weijerman ME, van Furth AM, van der Mooren MD, van Weissenbruch MM, Rammeloo L, Broers CJ, et al. Prevalence of congenital heart defects and persistent pulmonary hypertension of the neonate with Down syndrome. European journal of pediatrics. 2010; 169(10):1195-9. doi: 10.1007/s00431-010-1200-0 PMID: 20411274; PubMed Central PMCID: PMC2926442.
7. Saji T. Clinical characteristics of pulmonary arterial hypertension associated with Down syndrome. Pediatrics international: official journal of the Japan Pediatric Society. 2014; 56(3):297-303. doi: 10.1111/ped.12349 PMID: 24689825.
8. Cooney TP, Thurlbeck WM. Pulmonary hypoplasia in Down's syndrome. The New England journal of medicine. 1982; 307(19):1170-3. doi: 10.1056/NEJM198211043071902 PMID: 6214715.
9. Betsy L. Schloo M, Gordon F, Vawter M, Lynn M, Reid M. Down Syndrome: Patterns of disturbed lung growth. Human Pathology. 1990; 22(9):919-23.
10. Biko DM, Schwartz M, Anupindi SA, Altes TA. Subpleural lung cysts in Down syndrome: prevalence and association with coexisting diagnoses. Pediatric radiology. 2008; 38(3):280-4. doi: 10.1007/s00247-007-0699-3 PMID: 18097658.
11. Jakkula M, Le Cras TD, Gebb S, Hirth KP, Tuder RM, Voelkel NF, et al. Inhibition of angiogenesis decreases alveolarization in the developing rat lung. American journal of physiology Lung cellular and molecular physiology. 2000; 279(3):L600-7. PMID: 10956636.
12. Galambos C, Demello DE. Regulation of alveologenesis: clinical implications of impaired growth. Pathology. 2008; 40(2):124-40. doi: 10.1080/00313020701818981 PMID: 18203035.
13. Le Cras TD, Markham NE, Tuder RM, Voelkel NF, Abman SH. Treatment of newborn rats with a VEGF receptor inhibitor causes pulmonary hypertension and abnormal lung structure. American journal of physiology Lung cellular and molecular physiology. 2002; 283(3):L555-62. doi: 10.1152/ajplung.00408.2001 PMID: 12169575.
14. Le Cras TD, Kim DH, Markham NE, Abman AS. Early abnormalities of pulmonary vascular development in the Fawn-Hooded rat raised at Denver's altitude. American journal of physiology Lung cellular and molecular physiology. 2000; 279(2):L283-91. PMID: 10926551.
15. Grover TR, Parker TA, Balasubramaniam V, Markham NE, Abman SH. Pulmonary hypertension impairs alveolarization and reduces lung growth in the ovine fetus. American journal of physiology Lung cellular and molecular physiology. 2005; 288(4):L648-54. doi: 10.1152/ajplung.00288.2004 PMID: 15579625.
16. Abman SH. Impaired vascular endothelial growth factor signaling in the pathogenesis of neonatal pulmonary vascular disease. Advances in experimental medicine and biology. 2010; 661:323-35. doi: 10.1007/978-1-60761-500-2-21 PMID: 20204740.
17. Ryeom S, Folkman J. Role of Endogenous Angiogenesis Inhibitors in Down Syndrome. Journal of Craniofacial Surgery. 2009; 20(Suppl 1):595-6. PMID: 19795527
18. Zorick TS, Mustacchi Z, Bando SY, Zatz M, Moreira-Filho CA, Olsen B, et al. High serum endostatin levels in Down syndrome: implications for improved treatment and prevention of solid tumours. European journal of human genetics: EJHG. 2001; 9(11):811-4. doi: 10.1038/sj.ejhg.5200721 PMID: 11781696.
19. Kim YM, Hwang S, Kim YM, Pyun BJ, Kim TY, Lee ST, et al. Endostatin blocks vascular endothelial growth factor-mediated signaling via direct interaction with KDR/Flk-1. The Journal of biological chemistry. 2002; 277(31):27872-9. doi: 10.1074/jbc.M202771200 PMID: 12029087.
20. Yamaguchi N, Anand-Apte B, Lee M, Sasaki T, Fukai N, Shapiro R, et al. Endostatin inhibits VEG-Finduced endothelial cell migration and tumor growth independently of zinc binding. The EMBO journal. 1999; 18(16):4414-23. doi: 10.1093/emboj/18.16.4414 PMID: 10449407; PubMed Central PMCID: PMC1171516.
21. Mehta PD, Capone G, Jewell A, Freedland RL. Increased amyloid beta protein levels in children and adolescents with Down syndrome. Journal of the neurological sciences. 2007; 254(1-2):22-7. doi: 10.1016/j.jns.2006.12.010 PMID: 17275850.
22. Patel NS, Mathura VS, Bachmeier C, Beaulieu-Abdelahad D, Laporte V, Weeks O, et al. Alzheimer's beta-amyloid peptide blocks vascular endothelial growth factor mediated signaling via direct interaction with VEGFR-2. Journal of neurochemistry. 2010; 112(1):66-76. doi: 10.1111/j.1471-4159.2009.06426.x PMID: 19818105.
23. Baek K-H, Zaslavsky A, Lynch RC, Britt C, Okada Y, Siarey RJ, et al. Down's syndrome suppression of tumour growth and the role of the calcineurin inhibitor DSCR1. Nature. 2009; 459(7250):1126-30. doi: 10.1038/nature08062 PMID: 19458618
24. Qin L, Zhao D, Liu X, Nagy JA, Hoang MV, Brown LF, et al. Down syndrome candidate region 1 isoform 1 mediates angiogenesis through the calcineurin-NFAT pathway. Molecular cancer research: MCR. 2006; 4(11):811-20. doi: 10.1158/1541-7786.MCR-06-0126 PMID: 17114339.
25. Abman SH. Bronchopulmonary dysplasia: "a vascular hypothesis". American journal of respiratory and critical care medicine. 2001; 164(10 Pt 1):1755-6. doi: 10.1164/ajrccm.164.10.2109111c PMID: 11734417.
26. Stenmark KR, Abman SH. Lung vascular development: implications for the pathogenesis of bronchopulmonary dysplasia. Annual review of physiology. 2005; 67:623-61. doi: 10.1146/annurev.physiol.67.040403.102229 PMID: 15709973.
27. Bhatt AJ, Pryhuber GS, Huyck H, Watkins RH, Metlay LA, Maniscalco WM. Disrupted pulmonary vasculature and decreased vascular endothelial growth factor, Flt-1, and TIE-2 in human infants dying with bronchopulmonary dysplasia. American journal of respiratory and critical care medicine. 2001; 164(10 Pt 1):1971-80. doi: 10.1164/ajrccm.164.10.2101140 PMID: 11734454.
28. Greene AK, Kim S, Rogers GF, Fishman SJ, Olsen BR, Mulliken JB. Risk of vascular anomalies with Down syndrome. Pediatrics. 2008; 121(1):e135-40. doi: 10.1542/peds.2007-1316 PMID: 18166531.
29. Damico R, Kolb TM, Valera L, Wang L, Housten T, Tedford RJ, et al. Serum endostatin is a genetically determined predictor of survival in pulmonary arterial hypertension. American journal of respiratory and critical care medicine. 2015; 191(2):208-18. doi: 10.1164/rccm.201409-1742OC PMID: 25489667; PubMed Central PMCID: PMC4347439.
30. Sudhakar A, Sugimoto H, Yang C, Lively J, Zeisberg M, Kalluri R. Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by alpha v beta 3 and alpha 5 beta 1 integrins. Proceedings of the National Academy of Sciences of the United States of America. 2003; 100(8):4766-71. doi: 10.1073/pnas.0730882100 PMID: 12682293; PubMed Central PMCID: PMC153630.
31. Qi JH, Ebrahem Q, Moore N, Murphy G, Claesson-Welsh L, Bond M, et al. A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2. Nature medicine. 2003; 9(4):407-15. doi: 10.1038/nm846 PMID: 12652295.
32. Nyberg P, Xie L, Kalluri R. Endogenous inhibitors of angiogenesis. Cancer research. 2005; 65(10):3967-79. doi: 10.1158/0008-5472.CAN-04-2427 PMID: 15899784.
33. Hamano Y, Zeisberg M, Sugimoto H, Lively JC, Maeshima Y, Yang C, et al. Physiological levels of tumstatin, a fragment of collagen IV alpha3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via alphaV beta3 integrin. Cancer cell. 2003; 3(6):589-601. PMID: 12842087; PubMed Central PMCID: PMC2775452.
34. Vazquez F, Hastings G, Ortega MA, Lane TF, Oikemus S, Lombardo M, et al. METH-1, a human ortholog of ADAMTS-1, and METH-2 are members of a new family of proteins with angio-inhibitory activity. The Journal of biological chemistry. 1999; 274(33):23349-57. PMID: 10438512.
35. Park J, Oh Y, Chung KC. Two key genes closely implicated with the neuropathological characteristics in Down syndrome: DYRK1A and RCAN1. BMB reports. 2009; 42(1):6-15. PMID: 19192387.
36. Ayeni TI, Roper HP. Pulmonary hypertension resulting from upper airways obstruction in Down's syndrome. Journal of the Royal Society of Medicine. 1998; 91(6):321-2.; PubMed Central PMCID: PMC1296779. PMID: 9771520
37. D'Alto M, Mahadevan VS. Pulmonary arterial hypertension associated with congenital heart disease. European respiratory review: an official journal of the European Respiratory Society. 2012; 21(126):328-37. doi: 10.1183/09059180.00004712 PMID: 23204121.